Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

Objective: This study aimed to analyze the cost-effectiveness and biosimilar infliximab compared with conventional therapy in fireproof moderate to severe Crohn’s disease (CD) in Thailand.Materials and Methods: A Markov model was used to estimate the lifetime costs and health benefits of infliximab from a social perspective. Our analysis consisted of three treatment options (conventional therapies, infliximab originator and biosimilar) and three treatment scenarios (infliximab 2 years and 3 years if relapse, infliximab 2 years and life in prison if relapse, and infliximab for life). The input parameters obtained from the registry CD and a systematic review of the literature. The results are reported as the incremental cost-effectiveness ratio (icers) at 2017 USD per year quality adjusted life (QALY) gained. A sensitivity analysis was performed to assess the effect of parameter uncertainty. threshold of sensitivity analysis performed to determine the optimal drug prices.

Finally, the budget impact analysis conducted.Results: None of the scenarios that are cost effective in Thailand threshold willingness to pay (4706 USD / QALY gained). The lowest ICER 30,121 USD / QALY gained was reported in scenarios that included only standard biosimilar infliximab dose with a maximum of 5 years of treatment. Drug prices should be reduced by at least 72% to allow biosimilar infliximab to be cost-effective. The budgetary impact of 5 years only 695,958 USD for biosimilar price.Conclusions today: Infliximab for the treatment of moderate-to-severe CD fireproof in Thailand would be cost-effective if drug prices decreased significantly. The best value for money is a biosimilar infliximab strategy with limited duration of treatment.

Key pointsThe and biosimilar infliximab use in the limited duration of 5 years is not cost effective for patients with moderate to severe Crohn’s disease that is refractory to conventional therapy, but their prices were lowered by roughly 72-90% in Thailand. estimated impact of adopting the budget for the indication biosimilar infliximab or have potential for financial feasibility. Policy makers may consider the cost effectiveness and budget impact of the findings as well as other aspects such as the rarity of the disease as part of the decision making process.

 Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand
Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

The safety and effectiveness of biphasic insulin biosimilar in the management of diabetes mellitus during routine clinical practice in Asian Patients

Introduction: biosimilar insulin has the potential to improve access to treatment among patients with diabetes mellitus (DM), reduce treatment costs, and expand the market competition. There are no published studies evaluating the performance of biosimilar insulin in routine clinical practice in Asia. The study assessed the safety and effectiveness of biphasic insulin injections in diabetic patients isofan Malaysia.


Materials and methods: In this open-label, single-arm, observational, post marketing studies, patients received injections of biphasic insulin isofan appropriate Prescribing Information; and assessed for safety (side effects including hypoglycemia), effectiveness (glycosylated hemoglobin [HbA1c]; fasting blood sugar, [FBS], and the condition of the patient with the patient and physician) for 24 weeks.

Connection error.


Results: The patients with diabetic men and women (N = 119; diabetes mellitus type 2, n = 117) with a duration (SD) diabetes an average of 13 years were included. No new safety signals were identified. a significant reduction in HbA1c was observed at weeks 12 and 24 (mean [SD] – basic: 9.6% [1.9]; Week 12: 9.0% [1.7] and on Sunday, 24: 9, 1% [1.7]; p <0.001).